Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cisco Systems

Coca-Cola

Verizon

In this article, we cover five potential dividend growth ideas including Cisco Systems, IBM, Verizon, Gilead, and Coca-Cola.

Highlighting 5 Potential Dividend Yield Plays To Consider

Dr. Reddy's Labs

Ternium

Tired of expensive stocks being just of reach? Look abroad for some great buying opportunities.

3 Global Value Stocks to Buy Now

Bristol-Myers

FATE reports a wider Q1 loss on increased R&D expenses.

FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues

The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.

Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug

Gilead's FY 2020 results were fueled by Remdesivir. However, with the availability of vaccines, Remdesivir sales will fall.

Gilead Sciences: To Buy, Or Not To Buy - That Is The Question

Amazon

Twitter

CME Group

Discovery

Discovery Communications

S&P Global

ViacomCBS

With the trading day more than halfway over, the broader markets were sliding into the weekend.

Amazon, CME, Gilead, Twitter and More Friday Afternoon Analyst Calls

Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.

Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline

Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year. Sales of $6.42 billion missed the consensus of $6.74 billion but grew 16% Y/Y.

Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings

With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story.

Gilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2021 Results - Earnings Call Transcript

Gilead Sciences Inc. (NASDAQ: GILD) said on Thursday that its sales in the fiscal first quarter came in weaker than Wall Street estimates. Sales for its COVID-19 drug (Veklury), however, beat expectations.

4 key takeaways from Gilead Sciences Q1 earnings report

Gilead (GILD) delivered earnings and revenue surprises of 0.97% and -5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Q1 Earnings Beat Estimates

Gilead Sciences Inc on Thursday said its first-quarter product sales rose 16%, including $1.46 billion in sales of its COVID-19 antiviral drug remdesivir, but sales of flagship HIV and hepatitis C drugs were down due to the effects of the pandemic.

Gilead first-quarter profit rises despite lower HIV drug sales

Shares of Gilead Sciences (NASDAQ:GILD) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 23.81% year over year to $2.08, which missed the estimate of $2.09.

Recap: Gilead Sciences Q1 Earnings

Gilead Sciences Inc. reports a mixed quarter late Thursday, with sales below Wall Street expectations even as sales of its antiviral drug used to treat COVID-19 came in above forecast.

Earnings Results: Gilead stock falls as COVID-19 drug sales dwindle

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.71 per share of common stock for the second quarter of 2021. The dividend is payable on June 29, 2021, to stockholders of record at the close of business on June 15, 2021. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakt

Gilead Sciences Announces Second Quarter 2021 Dividend

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter 2021. “We have made strong progress in this first quarter, with our new partnership with Merck in long-acting HIV therapies, two newly approved indications in the U.S. for Trodelvy in metastatic triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex to our portfolio,” said Daniel O'Day, Chairman and Chief Executive Offi

Gilead Sciences Announces First Quarter 2021 Financial Results

GILD reports earnings Thursday. Analysts expect revenue to decline Q/Q. Veklury, its COVID-19 treatment, is a major catalyst. It has amplified growth in revenue and EBITDA.

Gilead Sciences' New Catalyst Could Shine Thursday

Vertex Pharmaceuticals

After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks at cheaper prices.

2 Must-Own Biotech Stocks to Buy in May

We believe that Gilead Sciences stock (NASDAQ﻿NDAQ﻿: GILD) is a good buying opportunity at the present time. GILD stock trades near $65 currently and it is, in fact, down 19% from its pre-Covid high of around $80 in March 2020 – before the coronavirus pandemic hit.

Should You Buy Gilead Stock At $65?

AbbVie

GlaxoSmithKline

Johnson & Johnson

Novartis

Merck

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

7 Pharmaceutical Stocks With Dividends in Hand

Amgen

AstraZeneca

Companies likely seeking bolt-on acquisitions, not mega-deals

Top Pharma Giants Expected to Be Most Active in M&A

As the number of Covid-19 infections explodes in India, drug companies have announced a number of efforts to get treatments to the country.

Merck and Gilead Sciences Sign Deals to Aid India's Covid-19 Fight

Shares of Gilead Sciences Inc. were up 0.1% in premarket trading on Tuesday, the day after the drug maker said it will donate 450,000 doses of its COVID-19 antiviral Veklury to India, which is undergoing an unprecedented surge in coronavirus cases, illnesses, and deaths. Gilead will also provide technical support to its seven licensing partners in India that manufacture remdesivir, and it will donate the active pharmaceutical ingredient used to make redmesivir, which is now called Veklury in the U.S. Gilead's stock is up 12.9% for the year, while the broader S&P 500 has gained 11.5%.

Gilead to donate 450,000 doses of COVID-19 drug to India

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that in response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licensing partners with technical assistance, support for the addition of new local manufacturing facilities and the donation of active pharmaceutical ingredient (API) to rapidly scale up production of remdesivir. Remdesivir is approved in India for restricted emergency use for the treatment of suspec

News for Gilead Sciences Stock (GILD)